Subject: Utilization pattern of minocycline (Minoz-OD) in real life scenario

Acne vulgaris is the formation of comedones, papules, pustules, nodules, and/or cysts as a result of obstruction and inflammation of pilosebaceous units. Treatment, based on severity, can involve a variety of topical and systemic agents directed at reducing sebum production, comedone formation, inflammation, and bacterial counts and at normalizing keratinization

Minocycline is a semi-synthetic second generation tetracycline class of antibiotic active against P. acne bacteria. It is fungistatic and acts via inhibition of bacterial protein synthesis. Minocycline OD is marketed by the Rigel team of Sun Pharmaceuticals Industries Ltd as Minoz OD.

Although every product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planed to conduct a prospective study to assess the real-life performance of ‘Minoz OD’tablet in acne patients.

We invite you to participate in this cross sectional study. All you need to do is to report on a standard form your experience with ‘Minoz OD’. Thus, this is not an experimental study.

If you agree to participate, you will need to copy the relevant information on to the standard data collection forms (which we call DCF).

Yours truly,

Mr.Sunil Jajjo
SVP and Cluster Head, Dermatology
Sun Pharmaceutical Industries Ltd.
Sun House CTS No. 201 B/1,
Western Express Highway,
Goregaon (E),
Mumbai - 400 063
Tel: + 91 22 4324 1234/4324